NCT06793748尚未招募1 期
An Adaptive Two-Part, Phase 1/2, Multi-Center, Double-Blinded, Randomized, Controlled Study of the Safety and Efficacy of Topically Applied PEP-TISSEEL in Participants With Chronic Radiation Ulcer
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Rion Inc.
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- Part 1(Phse1): Incidence of Treatment-Emergent Adverse Events (TEAEs) and Incidence of withdrawals from the study due to TEAEs
研究概览
简要总结
The goal of this clinical trial is to learn if drug Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (PEP-TISSEEL) works to treat chronic radiation ulcer in adults and compare it with comparator TISSEEL. It will also learn about the safety of drug PEP-TISSEEL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Phase 1 is open label, Phase 2 is controlled
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants in both study parts are eligible to be included if all of the following criteria apply:
- •Age and Sex
- •Males and females aged ≥ 18 years at the time of signing the informed consent. Informed Consent
- •Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Type of Participant and Disease Characteristics
- •Status post-radiation treatment, with radiation-induced ulcer. This includes participants with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations (this wound would otherwise be allowed to heal by secondary intention).
- •Index ulcer classified as Grade 1 to Grade 3 according to the NCI-CTCAE, Version 5.0
- •Area of index ulcer must be between 1 and 15 cm2 at screening and at randomization/baseline.
- •Have failed conservative treatments including attempts at washing and local wound care, and be seeking therapy
- •The chronic radiation ulcers are limited to cutaneous (skin) ulcers and not impacting mucosal (oral, nose, etc.) tissue. Sex and Contraceptive/Barrier Requirements
- •Must meet one of the following criteria:
- •a. Female participants of non-childbearing potential defined as : i. Postmenopausal for at least 1 year (participant verbal confirmation acceptable), or surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to screening); or ii. Bilateral tubal ligation more than 6 months prior to screening; or iii. Must have a negative β-hCG blood pregnancy test at screening and not be breastfeeding prior to being administered with the IP b. Male participants of non-childbearing potential are defined as those vasectomized participants whose vasectomy was performed 6 months prior to screening or those diagnosed as sterile by a physician c. Females and males of childbearing potential who practice an acceptable method of contraception defined as the use of any form of hormonal contraceptive, a barrier method with spermicide, condoms, intrauterine device, or abstinence from sexual intercourse starting at least 60 days prior to screening and continuing at least 30 days following the last treatment. Female will undergo pregnancy tests and must have a negative β-hCG blood pregnancy test at screening visit and negative urine pregnancy test at baseline visit and must not be breastfeeding prior to being administered with the IP. Other Inclusion Criteria
- •Participants must be deemed by Radiation Oncologist at or greater than 6 months status/post-treatment to be without evidence of local recurrence
- •Ability to comply with the study protocol
- •Participants must be willing to undergo all clinical investigation-related procedures and attend all required visits including all follow-up visits Exclusion Criteria
- •Participants in both study parts are excluded if any of the following criteria apply:
- •Medical Conditions
- •Study wound exhibits clinical signs and symptoms of infection at the screening visit
- •Any participant that has vascular compromise that is untreated as defined by as by defined abnormal invasive or non-invasive vascular studies
- •The index ulcer is within 2 cm of any other ulcer
- •The non-Cutaneous CRUs and ulcers impacting mucosal (oral, nose, etc.) tissue Liver Safety
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN) Prior/Concurrent Clinical Study Experience
- •Use of investigational drugs or biologics within 28 days prior to screening
- •Participation in another interventional clinical study in the past 30 days or concurrent participation in another interventional clinical study Diagnostic Assessments
- •Hemoglobin A1c (HbA1c) > 8%
- •Serum creatinine l > 2.5 mg/dL
- •Absolute neutrophil count of <500 neutrophils per mm3 over the course of enrollment
- •Positive test for HBV, HCV, HIV Other Exclusion Criteria
- •Active tanning, including the use of tanning booths, during the course of the study
- •Any participant who would be unable to safely monitor the infection status of the index ulcer at home and return for scheduled visits
- •Any participant with a life expectancy ≤ 6 months
- •Pregnancy, including a positive pregnancy test at screening, or lactation
- •Likely inability to comply with the protocol or cooperate fully with the Investigator and study site personnel
- •Known or suspected active abuse of alcohol, or non-prescription drugs
- •Participants who are incarcerated for any reason
排除标准
- 未提供
研究组 & 干预措施
Part 1-PEP-TISSEEL
Experimental
Part 1(Phase1): Participants in the PEP-TISSEEL group will receive 1 topical application per week of 2 vials of PEP + 10 mL TISSEEL for 20 weeks (5 months).
干预措施: PEP-TISSEEL (Combination Product)
Part 1(Phase1) -TISSEEL-Only
Placebo Comparator
Part 1:Participants in the TISSEEL-Only group will receive 1 topical application per week of 10 mL TISSEEL for 20 weeks (5 months).
干预措施: TISSEEL Fibrin Sealant KIT (Drug)
Part 2 (Phase2)-PEP-TISSEEL
Experimental
Part 2: Participants in the PEP-TISSEEL group will receive 1 topical application per week of 2 vials of PEP + 10 mL TISSEEL for 20 weeks (5 months).
干预措施: PEP-TISSEEL (Combination Product)
Part 2(Phase2)-TISSEEL-Only
Placebo Comparator
Part 2:Participants in the TISSEEL-Only group will receive 1 topical application per week of 10 mL TISSEEL for 20 weeks (5 months).
干预措施: TISSEEL Fibrin Sealant KIT (Drug)
结局指标
主要结局
Part 1(Phse1): Incidence of Treatment-Emergent Adverse Events (TEAEs) and Incidence of withdrawals from the study due to TEAEs
时间窗: 20 week
Part 2 (Phase2): The proportion of participants with complete wound closure during the 20 weeks of the Treatment Phase
时间窗: 20 weeks
Complete wound closure of the index ulcer is defined as 100% re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart
次要结局
- Part 1(Phase1): The proportion of participants with complete wound closure during the 20 weeks of the Treatment Phase(20 weeks)
- Part 2(Phase2): Wound area change (%) during the 20 weeks of the Treatment Phase(20 weeks)
- Part 2(Phase2): Time to complete wound closure during the 20 weeks of the Treatment Phase(20 weeks)
- Part 2(Phase2):Incidence of Treatment-Emergent Adverse Events (TEAEs)(20 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)Esophageal Anastomotic LeakNCT03847857Sun Yat-sen University360
已完成
2 期
Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift ProceduresFacial Rhytidectomy (Face-lift)NCT00708071Baxter Healthcare Corporation45
已完成
2 期
BI 10773 add-on to Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00749190Boehringer Ingelheim495
撤回
3 期
Empyema Treated With tPA & DNAseEmpyemaNCT01862458Children's Mercy Hospital Kansas City
已完成
2 期
Lipid Infusion in Dialysis Patients With EndotoxemiaFatigueEnd Stage Renal Disease (ESRD)NCT00506454Sepsicure22